Hemogenyx Pharmaceuticals Plc

LSE:HEMO Stock Report

Market Cap: UK£16.1m

Hemogenyx Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Vladislav Sandler

Chief executive officer

UK£397.0k

Total compensation

CEO salary percentage98.0%
CEO tenure10.9yrs
CEO ownership3.1%
Management average tenureno data
Board average tenure7.1yrs

Recent management updates

Recent updates

Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?

Aug 21
Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?

Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?

May 04
Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?

We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully

Jan 06
We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully

Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?

Oct 09
Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?

CEO Compensation Analysis

How has Vladislav Sandler's remuneration changed compared to Hemogenyx Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-UK£5m

Mar 31 2024n/an/a

-UK£6m

Dec 31 2023UK£397kUK£389k

-UK£7m

Sep 30 2023n/an/a

-UK£7m

Jun 30 2023n/an/a

-UK£7m

Mar 31 2023n/an/a

-UK£6m

Dec 31 2022UK£282kUK£276k

-UK£4m

Sep 30 2022n/an/a

-UK£3m

Jun 30 2022n/an/a

-UK£3m

Mar 31 2022n/an/a

-UK£4m

Dec 31 2021UK£213kUK£206k

-UK£5m

Sep 30 2021n/an/a

-UK£5m

Jun 30 2021n/an/a

-UK£5m

Mar 31 2021n/an/a

-UK£3m

Dec 31 2020UK£205kUK£200k

-UK£2m

Sep 30 2020n/an/a

-UK£2m

Jun 30 2020n/an/a

-UK£2m

Mar 31 2020n/an/a

-UK£2m

Dec 31 2019UK£149kUK£145k

-UK£1m

Sep 30 2019n/an/a

-UK£2m

Jun 30 2019n/an/a

-UK£2m

Mar 31 2019n/an/a

-UK£2m

Dec 31 2018UK£98kUK£94k

-UK£2m

Sep 30 2018n/an/a

-UK£2m

Jun 30 2018n/an/a

-UK£3m

Mar 31 2018n/an/a

-UK£3m

Dec 31 2017UK£79kUK£79k

-UK£2m

Compensation vs Market: Vladislav's total compensation ($USD497.46K) is above average for companies of similar size in the UK market ($USD354.03K).

Compensation vs Earnings: Vladislav's compensation has increased whilst the company is unprofitable.

CEO

Vladislav Sandler (59 yo)

10.9yrs

Tenure

UK£397,000

Compensation

Dr. Vladislav Sandler, Ph D., is a Co-Founder of Hemogenyx Pharmaceuticals Plc. and serves as its Chief Executive Officer since December 2013 and serves as its Director.Dr. Sandler also serves as Chief Ex...

Board Members

NamePositionTenureCompensationOwnership
Vladislav Sandler
Co-Founder7.1yrsUK£397.00k3.1%
£ 498.5k
Alexis Sandler
Independent Co-Founder & Non-Executive Director7.1yrsUK£60.00k5.6%
£ 901.1k
Koen Van Besien
Clinical Advisor & Medical Directorno datano datano data
H. Shepard
Member of Scientific Advisory Board6.7yrsno datano data
Peter Redmond
Independent Non-Executive Director9.3yrsUK£50.00k0.42%
£ 67.2k
Marc Feldmann
Independent Chairman & Chairman of Advisory Board7.2yrsUK£15.00kno data

7.1yrs

Average Tenure

74yo

Average Age

Experienced Board: HEMO's board of directors are considered experienced (7.1 years average tenure).